Sensus Healthcare CEO On Republican Government: 'Our Product Can Survive'

Sensus Healthcare Inc SRTS is micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO Joseph C. Sardano, who shared some insight into the company, its IPO and its financial situation and his prospects for the business under a Republican controlled House, Senate and White House.

The Trump Era

“There’s a lot of people [who] are concerned with where healthcare might be going, where it’s been,” he began.

However, Sensus’ management team has a combined experience in healthcare of over 130 years, he added. “We took very strong efforts when we started this company, to look into what the future of healthcare could be, regardless of who was in charge of healthcare and who was in charge of the government.”

“Some of the things that we have focused on, which I think transpires any ideology or whoever the government could be, is the fact that we know that there is going to be specific challenges on technologies that are going to come into play that are not going to be cost-effective, or provide the outcomes that are either as good or better than is being currently achieved in the healthcare market,” he voiced.

“So, when we developed this technology, we were extremely confident in the cost-effectiveness. It could survive all of the efforts to provide excellent remedies for maladies that require a lot of attention, and require excellent outcomes. That has been our theme from day one,” Sardano went on.

A Strong Position

“We currently have a technology that is extremely cost effective, it has the opportunity of treating patients better than anything that exists today – that is much more expensive, and we continue to focus on that by expanding the indications of the existing technology,” the chief executive assured.

“In other words, [we continue to focus on] using that technology and making sure that it gives the physicians and patients more choices in treating their problems with less cost.”

“I think this is beneficial from the physician proposition, the patient proposition, and the healthcare proposition. So, we’ve been ahead of this curve ever since we started the company. So, we are very confident that, if there is a product out there that can survive any and all pressures and challenges from a cost standpoint, this is the one that can do that, because it’s just that cost-effective,” he concluded.

Check out our conversation with Synergy Pharmaceuticals Inc SGYP's chief strategist, who discussed recent results and upcoming catalysts.